(Total Views: 755)
Posted On: 01/29/2021 4:24:31 PM
Post# of 154062
For me, this was the most significant news coming out of today's (or last night's presentation). It should lay to rest several nagging questions:
- Dr. Janet Woodcock is a proponent. Significant upgrade from Dr. Hahn.
- The FDA is not slow walking leronlimab for Covid. The FDA truly were waiting for CD12 full trial results to act. And this sense of urgency is clealy being displayed.
- With both Amerex and FDA biostatisticians working in parallel, results will come out sooner rather than later. Correspondingly, any potential EUA and/or full approval will be expedited since the FDA will already be familiar with the trial results and won't need to take time to go over Amerex's report.
- Dr. Janet Woodcock is a proponent. Significant upgrade from Dr. Hahn.
- The FDA is not slow walking leronlimab for Covid. The FDA truly were waiting for CD12 full trial results to act. And this sense of urgency is clealy being displayed.
- With both Amerex and FDA biostatisticians working in parallel, results will come out sooner rather than later. Correspondingly, any potential EUA and/or full approval will be expedited since the FDA will already be familiar with the trial results and won't need to take time to go over Amerex's report.
(15)
(0)
